Briacell Therapeutics (BCTXL) Stock Price, News & Analysis
Company Description
Briacell Therapeutics (NASDAQ: BCTXL) is classified in the Pharmaceutical Preparations sector.
For FY2025, Briacell Therapeutics reported net income of -$26.3M and diluted earnings per share of $-62.19.
This page collects what Stock Titan holds for BCTXL, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Briacell Therapeutics (BCTXL) stock last closed at $0.9200.
BCTXL Rankings
Latest News
SEC Filings
Briacell Therapeutics has filed 5 recent SEC filings, including 3 Form 8-K, 1 Form 424B5, 1 Form 25-NSE. The most recent filing was submitted on June 26, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all BCTXL SEC filings →
Financial Highlights
operating income reached -$27.2M, and net income was -$26.3M. Diluted earnings per share stood at $-62.19. The company generated -$28.2M in operating cash flow. With a current ratio of 3.42, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Briacell Therapeutics (BCTXL) currently stands at 8.4 thousand shares, up 24.0% from the previous reporting period.
Days to Cover History
Days to cover for Briacell Therapeutics (BCTXL) currently stands at 1.4 days, up 42% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has increased 42% over the past year, indicating either rising short interest or declining trading volume.
BCTXL Company Profile & Sector Positioning
Briacell Therapeutics (BCTXL) operates in the Pharmaceutical Preparations sector and is listed on the NASDAQ.